Ocular safety of fluticasone furoate nasal spray in patients with perennial allergic rhinitis: A 2-year study

Annals of Allergy, Asthma and Immunology

Volumn 111, Issue 1, 2013, Pages 45-50

  Laforce, Craig ^a   Journeay, Glen E ^b   Miller, S David ^c   Silvey, Mary Jane ^d   Wu, Wei ^d   Lee, Laurie A ^d   Chylack Jr , Leo T ^e,f  

^a North Carolina Clinical Research   (United States)

^b Austin Clinical Research Inc   (United States)

^c Northeast Medical Research Associates   (United States)

^d GLAXOSMITHKLINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Chylack Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE FUROATE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CATARACT; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; EYE; EYE EXAMINATION; EYE TOXICITY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE SEPTUM ULCER; NOSE ULCER; PATIENT COMPLIANCE; PERENNIAL RHINITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SURVIVAL; TREATMENT DURATION; UNITED STATES; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; CATARACT; CHILD; DOUBLE-BLIND METHOD; EPISTAXIS; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; NASAL SPRAYS; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879552233     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2013.04.013     Document Type: Article

References (10)

1. M.S. Blaiss Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis Allergy Asthma Proc 32 2011 413 418
2. A. Rosenblut, P.G. Bardin, and B. Muller Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis Allergy 62 2007 1071 1077
3. Veramyst® (fluticasone furoate) Nasal Spray [prescribing information] August 2011 GlaxoSmithKline Research Triangle Park, NC
4. J.A. Davison, and L.T. Chylack Clinical application of the lens opacities classification system III in the performance of phacoemulsification J Cataract Refract Surg 29 2003 138 145
5. G. Benčić, M. Zorić-Geber, D. Šarić, M. Čorak, and Z. Mandić Clinical importance of the lens opacities classification system III (LOCS III) in phacoemulsification Coll Antropol 29 suppl 1 2005 91 94
6. L.T. Chylack Jr., J.K. Wolfe, and D.M. Singer The Longitudinal Study of Cataract Study Group. The Lens Opacities Classification System III Arch Ophthalmol 111 1993 831 836
7. M.C. Leske, S.Y. Wu, B. Nemesure, X. Li, A. Hennis, and A.M. Connell Incidence and progression of lens opacities in the Barbados Eye Studies Ophthalmology 107 2000 1267 1273
8. L.S. Lim, R. Husain, G. Gazzard, S.K. Seah, and T. Aung Cataract progression after prophylactic laser peripheral iridotomy: potential implications for the prevention of glaucoma blindness Ophthalmology 112 2005 1355 1359
9. R. Husain, L. Tong, and A. Fong Prevalence of cataract in rural Indonesia Ophthalmology 112 2005 1255 1262
10. D. Bross-Soriano, C. Hanenberg-Milver, J. Schimelmitz-Idi, J.R. Arrieta-Gomez, R. Astorga del Toro, and G. Bravo-Escobar Effects of three nasal topical steroids in the intraocular pressure compartment Otolaryngol Head Neck Surg 130 2004 187 191